Catálogo de publicaciones - libros
CD4+CD25+ Regulatory T Cells: Origin, Function and Therapeutic Potential
R.W. Compans ; M.D. Cooper ; T. Honjo ; H. Koprowski ; F. Melchers ; M.B.A. Oldstone ; S. Olsnes ; M. Potter ; P.K. Vogt ; H. Wagner ; Bruno Kyewski ; Elisabeth Suri-Payer (eds.)
Resumen/Descripción – provisto por la editorial
No disponible.
Palabras clave – provistas por la editorial
Immunology
Disponibilidad
| Institución detectada | Año de publicación | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | 2005 | SpringerLink |
Información
Tipo de recurso:
libros
ISBN impreso
978-3-540-24444-8
ISBN electrónico
978-3-540-27702-6
Editor responsable
Springer Nature
País de edición
Reino Unido
Fecha de publicación
2005
Información sobre derechos de publicación
© Springer-Verlag Berlin Heidelberg 2005
Cobertura temática
Tabla de contenidos
Regulatory T Cells in Transplantation Tolerance
H. Waldmann; L. Graca; E. Adams; P. Fairchild; S. Cobbold
Our ability to harness tolerance mechanisms will have a major impact in organ transplantation if it becomes possible to minimize drug maintenance, or even wean off immunosuppressive drugs. An improved understanding of the biology of regulatory T cells will make it possible to replace current induction regimens with those favouring the vaccination and selection of T cells that prevent graft rejection. Once tolerance is established, the continuous supply of graft antigens should sustain T cell mediated regulation as the dominant mechanism preventing graft rejection.
Part II - Involvement of Disease Models | Pp. 249-264
CD4CD25 Regulatory T Cells in Hematopoietic Stem Cell Transplantation
P. Hoffmann; J. Ermann; M. Edinger
Allogeneic hematopoietic stem cell transplantation (SCT) is a well-established treatment modality for malignant and nonmalignant hematologic diseases. High-dose radio-and/or chemotherapy eradicate the hematopoietic system of the patient and induce sufficient immunosuppression to enable donor stem cell engraftment. The replacement of the recipient’s immune system with that of the donor significantly contributes to the success of this treatment, since donor immune cells facilitate stem cell engraftment, provide protection from infections, and eliminate residual malignant or nonmalignant host hematopoiesis, thereby protecting from disease relapse in patients transplanted for leukemia or lymphoma (graft-versus-leukemia effect, GVL). Mediators of these beneficial effects are mature T cells within the stem cell graft. However, donor T cells can also attack host tissues and induce a life-threatening syndrome called graft-versus-host disease (GVHD). The challenge of allogeneic SCT is to find a balance between beneficial and harmful T cell effects, which at present is only insufficiently achieved by the use of immunosuppressive drugs. In the future, it might be possible to replace or support such medications by using the intrinsic regulatory capacity of the transplanted immune system, as represented by T cell subpopulations with suppressive activity, such as CD4CD25 regulatory T (T) cells. In various mouse model systems, these cells have been shown to suppress GVHD while preserving the GVL effect. As the characterization of their human counterparts is rapidly progressing, their application in allogeneic SCT might soon be explored in clinical trials.
Part II - Involvement of Disease Models | Pp. 265-285
Naturally Arising CD25CD4 Regulatory T Cells in Tumor Immunity
T. Nomura; S. Sakaguchi
Naturally arising regulatory T (T) cells, represented by CD25CD4 T cells, play an essential role in maintaining immunological self-tolerance. This T cell-mediated dominant control of the immune response not only inhibits the development of autoimmune disease, but also impedes effective immunosurveillance against autologous tumor cells. Attenuation of T cell-mediated immune suppression can therefore evoke effective tumor immunity in otherwise nonresponsive animals. This common regulatory mechanism for autoimmunity and tumor immunity can be exploited when devising a novel immunotherapy for cancer.
Part II - Involvement of Disease Models | Pp. 287-302
Phenotypic and Functional Differences Between Human CD4CD25 and Type 1 Regulatory T Cells
M. K. Levings; M. G. Roncarolo
T regulatory (Tr) cells have an essential role in the induction and maintenance of tolerance to both and foreign self-antigens. Many types of T cells with regulatory activity have been described in mice and humans, and those within the CD4 subset have been extensively characterized. CD4 Type-1 regulatory T (Tr1) cells produce high levels of IL-10 and mediate IL-10-dependent suppression, whereas the effects of naturally occurring CD4CD25 Tr cells appear to be cell-contact-dependent. Tr1 cells arise in the periphery upon encountering antigen in a tolerogenic environment. In contrast, it appears that CD4CD25 Tr cells can either arise directly in the thymus or be induced by antigen in the periphery. We have been interested in defining the phenotype and function of different subsets of CD4 Tr cells present in human peripheral blood, with the ultimate aim of designing therapeutic strategies to harness their immunoregulatory effects. This review will discuss the similarities and differences between human Tr1 and naturally occurring CD4CD25 Tr cells, as well as evidence that indicates that they have nonoverlapping, but synergistic roles in immune homeostasis.
Part II - Involvement of Disease Models | Pp. 303-326